Article
Breast cancer screening adherence after multigene panel testing among women with pathogenic variants in moderate-risk genes or with empirically increased breast cancer risk.
Breast cancer research and treatment - 10 Jul 2026
Comeaux Jacob G, Gutierrez Natalia, Ricker Charité N, Nie Qi, Nguyen Averi, Garcia Ivan, Chang Emmeline Y, Waggoner Rebecca M, Groshen Susan, Lerman Caryn, Spicer Darcy, Culver Julie O
Abstract excerpt
PURPOSE: To identify factors associated with adherence to breast cancer (BC) screening among women with a pathogenic or likely pathogenic (P/LP) variant in a moderate-risk gene, ATM, BARD1, CHEK2, RAD51C, and RAD51D or with empiric lifetime risk ≥ 20%. METHODS: We reviewed medical records of women without breast cancer who underwent genetic counseling and testing and were advised to undergo annual breast MRI and...
Topics
Join the communities discussing this publication.